Therapy / Class:
Therapy: Anti-Inflammatory & Immunosuppressant
Class: Corticosteroids
Mechanism of Action:
It is a corticosteroid prodrug with an active metabolite, 21-deflazacort, which binds to the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects on the body.
Indications:
- Duchenne Muscular Dystrophy (DMD) in patients 5 years of age and old
Also, in… - Rheumatoid Arthritis
- Juvenile Chronic Arthritis
- Asthma
- Pemphigus
- Uveitis
- Nephrotic Syndrome
- Immune Suppression in Transplantation
Dosage & Administration:
Allergic & Inflammatory Disorders
Child: 0.25-1.5mg/kg/Day given on alternate Days
Duchenne Muscular Dystrophy
Under 5yrs: Safety & Efficacy not established.
Above 5 Yrs.: 0.9mg/kg/Day Once orally everyday
HOW SUPPLIED: FITCORT is available as suspension in 30ml pack.
References:
- Campbell C, Jacob P. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurol. 2003 Sep 8;3:7.2.Dooley M, Spencer CM, Dunn CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs. 2001;61(9):1351-78.
- Griggs RC, Miller JP, Greenberg CR, Fehlings DL, Pestronk A, Mendell JR, Moxley RT 3rd, King W, Kissel JT, Cwik V, Vanasse M, Florence JM, Pandya S, Dubow JS, Meyer JM. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016 Nov 15;87(20):2123-2131.
- Loftus JK, Reeve J, Hesp R, David J, Ansell BM, Woo PM. Deflazacort in juvenile chronic arthritis. J Rheumatol Suppl. 1993 Apr;37:40-2.
